Friday, September 30, 2011

Geron week in review

Geron closed at $2.12 on Friday. The high for the week was $2.31 on Sept 30 and the low was $2.09 on Sept 26. The 50 day moving average is $2.49 which I think it will break in a few months. The new CEO John Scarlett brings on extensive track record of drug development and commercialization success. We will not have another secondary offering. Maybe when it hits $10.

Good luck in this rigged casino

Thursday, September 29, 2011

Geron new CEO

John Scarlett is Geron's new CEO. He has 25 years of executive leadership.  A Biotechnology Industry Veteran Brings Extensive Track Record of Drug Development and Commercialization Success.
Conference Call/Webcast Scheduled for 9:00 A.M. ET Tomorrow
This is great news there will be no more secondary stock of offerings. Maybe at $20+. Mr. Scarlett          would not take the job unless he saw a great opportunity. Again I feel this is a great move by Geron.       

Good luck in this rigged casino

                

Geron Longs will be rewarded

The true believers in the science, know in the not-too-distant future, the science will trump the market and all long-term investors will be handsomely rewarded. Keep the faith, buy the dips and sell the rips up. Trade around your core holdongs. I buy a few shares on the dips and when it goes up 20-30 cents I sell. Always remember you can lose all your money in any stock.

Good luck in this rigged casino

Wednesday, September 28, 2011

Geron the best

Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases. The company is advancing anti-cancer therapies through multiple Phase 2 clinical trials in different cancers by targeting the enzyme telomerase and with a conpound designed to penetrate the blood-brain barrier. The four Phase 2 trials end in Q4 of 2012 results shouuld be in Dec 2012. The company is developing cell therapies from differentiated human embryonic stem cells for a range of indications, with the first product in a Phase 1 clinical trial for spinal cord injury. Four patients are now in the trial. For more infor visit www.geron.com .
On this blog I will be stating news that may move the stock up or down. Will be stating my trades. Showing , hopefully how I make money while waiting for the big price move up to $100 a share. A dream, maybe. This stock could do it.